Skip to main content

KIYATEC Assay Hits the Mark in Study to Predict Patient Response to First Line Ovarian Cancer Drugs

By August 16, 2019February 18th, 2020No Comments

Company’s Ovarian Assay is the First in a Series of Planned Indications Using EV3D Technology Platform Optimized for Solid Tumors

GREENVILLE, S.C.– August 1, 2019 – KIYATEC, Inc. today announces that results from its prospective, multi-center pilot study, to investigate their assay’s predictive accuracy and correlation to outcome among newly diagnosed ovarian cancer patients, have been published in Scientific Reports. Study findings represent both a preliminary clinical validation for the company’s ovarian cancer assay and a significant developmental milestone for the assay’s technology platform, known as Ex Vivo 3D Cell Culture (EV3D).

Click HERE to read more.